Skip to main content
Premium Trial:

Request an Annual Quote

New Products: CTGT's Connective Tissue Disorder Tests


Connective Tissue Gene Tests, or CTGT, this week announced the availability of 33 new tests using its next-generation sequencing and microarray technologies.

Twenty of the new panels can be run on its High-Density Targeted Array platform, an Agilent Technologies-manufactured chip for copy number variation detection.

These include tests for genes associated with different types of spondylocostal dysotosis, Norrie disease, pseudoxanthoma elasticum, serpentine fibula-polycystic kidney syndrome, Alagille syndrome, arterial calcification, cleidocranial dysplasia, Ehlers-Danlos syndrome, exudative vitreoretinopathy, Hajdu-Cheney syndrome, hereditary hemorrhagic telangiectasia, and metaphyseal dysplasia.

The Allentown, Pa.-based company charges $1,190 per first gene tested with the array and $590 per additional genes tested.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.